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Abstract
Iron is an essential mineral that is vital for growth development, normal cellular function, synthesis of hormones and connective tissue, and 
most importantly, serves as a component of hemoglobin to carry oxygen to body tissues. The body finely regulates the amount of circulating 
and stored iron within the body to maintain concentration levels within range for optimal physiologic function. Without iron, the ability for 
cells to participate in electron transport and energy metabolism decreases. Furthermore, hemoglobin synthesis is altered, which leads to anemia 
and decreased oxygen delivery to tissue. Problems arise when there is too little or too much iron. This review explores the role of the liver in 
iron physiology, iron overload and discusses the most common causes of primary and secondary hepatic iron overload.
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Introduction
Iron is an essential mineral vital for growth development, 
normal cellular function, synthesis of  hormones, and con-
nective tissue and serves as a component of  hemoglobin 
to carry oxygen to body tissues (1). The body finely regu-
lates the amount of  circulating and stored iron to maintain 
concentration levels within range for optimal physiologic 
function (2,3). Without iron, the ability of  the cells to 
participate in electron transport and energy metabolism 
decreases. Furthermore, hemoglobin synthesis is altered, 
which leads to anemia and reduced oxygen delivery to 
tissue.
Problems arise when there is too little or too much iron. In 
excess, iron is toxic, as free-flowing iron can form free radicals 
via oxidation-reduction reactions (2). Over time, iron excess 
causes long-term damage to the liver, heart, pancreas, pituitary, 
joints, and skin. Effects of iron overload (IO) are often insid-
ious and not noticed until widespread tissue damage occurs, 
leading to irreversible changes such as cirrhosis,  diabetes, and 
arthropathies (3). There are many causes of iron overload 
including genetic disorders, nonalcoholic liver disease, and 
responses to acute systemic inflammation or infections.
This review explores the role of the liver in iron physiol-
ogy, iron overload and discusses the most common causes of 
primary and secondary hepatic iron overload.
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Iron Absorption
The acquisition of iron in a healthy adult is obtained solely 
through the daily dietary intake (1). In western diets, meats 
and green leafy vegetables provide an adequate amount 
of iron to avoid depletion. Upon consumption of an iron- 
containing substance, iron is converted from ferric iron (Fe3+) 
to ferrous iron (Fe2+) by intestinal ferric reductase and duo-
denal cytochrome b(dcytb) reductase (4). An increase in 
acidity at the enterocyte’s brush border provides a hydrogen 
electrochemical gradient that drives the ferrous form of iron 
into the cell. Following uptake, Fe2+ is subsequently trans-
ported from the enterocyte’s luminal side into the epithelial 
cell through either a heme transporter (4), endosome, and/or 
a divalent metal transport 1 (DMT 1) (2,3,5,6). 
If  the body requires iron, it is transported to the basolat-
eral membrane by ferroportin (FPN)-1 in association with 
hephaestin and plasma ceruloplasmin (7). Once iron inter-
acts with hephaestin and gets converted into the ferric state, 
the state needed for absorption, the iron molecule binds to 
plasma transferrin. If  iron is not required, it becomes seques-
tered and stored within the cell and expelled along with the 
enterocyte shedding at the end of its cellular life.
In contrast, heme-iron crosses the enterocyte border with-
out the need for reduction to the ferric state. It is hypothe-
sized that iron is released from heme within the enterocyte 
and is similarly exported into the bloodstream via FPN-1 
(4,7). The body recognizes “need” by the function of fer-
roportin, which is negatively regulated by the regulatory 
hormone-hepcidin.
Iron Uptake
Iron alone is extremely reactive. If  iron is not bound by spe-
cific serum carriers and/or storage proteins within the body, 
it can viciously interact with vascular, cellular, and subcel-
lular structures (8). Therefore, after absorption, it is bound 
to the plasma protein transferrin (TF) for safe transport. TF 
is a bilobed glycoprotein that consists of two binding sites 
for iron (2,3,9). Plasma protein affinity allows only five Fe3+ 
iron molecules to be present at any given time in a healthy 
adult bloodstream (4). This high affinity prevents free iron 
from surviving in the bloodstream (4). Iron is then distrib-
uted throughout the body to tissues and stored within cells as 
Ferritin ( Figure 1) (2,3,5,9).
TF circulates until it interacts with a specific receptor 
called the transferrin receptor (TfR), which is found on 
cells with the highest iron demands. These cells include red 
blood cells (RBCs) and other rapidly dividing cells (4). Even 
though transferrin receptors are found on many additional 
cell types around the body, the highest are found in a devel-
oping erythroblast. TfR allows the iron molecules to bind 
and transport iron intracellularly (4). The transferrin-iron 
complex exists in two forms: monoferric (consists of one iron 
molecule) or diferric (presence of two iron molecules). In an 
intelligent physiologic fashion, the TfR has a higher affinity 
for the diferric form. In contrast, TfR has the lowest affinity 
for apo TF, which does not carry iron (4).
Once iron binds to TF, the complex travels to the desig-
nated tissue to interact with its receptor (10). The TF-TfR 
complex forms a cluster in the cell membrane on the cell sur-
face and is later internalized as a clathrin-coated vesicle (10). 
Once in the cytosol, this vesicle will fuse with the endosome 
to release iron from TF under acidic conditions (10). Acidifi-
cation is a crucial step for the conformational protein change 
to release the iron molecule. However, DMT-1 must reduce 
the iron molecule to its ferrous form to be transported out 
of the endosome (6,10), which is accomplished by an antigen 
called six-transmembrane epithelial antigen of the prostate 
3 (10). Following this release, the now apo TF, without iron 
and Tfr complex stays coupled until it returns to the cellular 
membrane where the pH is more neutral (10). At this stage, 
the complex will separate, and the apo TF will re-enter the 
plasma to search for more iron, and the cell can now utilize 
the released intracellular iron.
Within an erythroblast, any excess iron formed during 
hemoglobin synthesis gets converted into “ferritin.” This 
storage mechanism also occurs in other cells, specifically 
within the liver parenchymal cells, and plays a crucial role in 
incorporating iron into heme-containing enzymes (4). Iron 
already incorporated into hemoglobin will enter the human 
circulation as new RBCs released from the bone marrow. The 
iron will become part of that red cell mass and cannot be 
reutilized until the RBC dies (4). At the end of the RBCs life 
span, the reticuloendothelial (RE) system recognizes senes-
cent cells (4). Here it undergoes phagocytosis, with the hemo-
globin forming globin and heme (10). 
The resultant iron is then shuttled back to the RE cell’s sur-
face, which TF can recognize, and the cycle restarts anew (10).
Iron Regulation
In a healthy adult, about 30% of TF binding sites are uti-
lized (2,3). Many unoccupied binding sites (~70%) serve 
as an essential buffer in improper or excess iron absorp-
tion through the gastrointestinal tract. If  TF binding sites 
become saturated, as occurs in iron overload disorders, iron 
is left unbound in its free form, known as non-transfer-
rin-bound iron (NTBI). High NTBI levels are problematic, 
as the cells and parenchyma that line the body’s organs have 
no defense against the effect of free iron (2,3,5,9). The body 
recognizes when TF saturation is becoming high, thus acti-
vating a feedback mechanism to signal the body to decrease 
iron absorption. 
On average, the human body maintains approximately 4 g 
of iron (11). It is estimated that the body absorbs 10% of 
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Figure 1: Iron metabolism and distribution.
10–20 mg of dietary iron (1–2 mg daily) through the gas-
trointestinal tract. Subsequently, in a cyclical hemostatic 
fashion, the body also loses old iron at a rate of 1–2 mg/day 
through sweating, urine, and feces (12). Apart from diet, the 
body can also accumulate iron through iatrogenic causes, 
such as excess oral iron supplementations, erythrocyte infu-
sions, or iron transfusions for treatment of certain medical 
conditions (13,14). The question arises, how is iron metabo-
lism regulated? The answer to this is complicated, and it lies 
at the biochemical level involving cytoplasmic mRNA. For 
diferric transferrin to couple with TfR-1, this receptor needs 
to be synthesized by the induction and sensing of iron defi-
ciency (4). Normally excess iron inhibits TfR-1 synthesis by 
destabilizing its mRNA through the interaction of iron regu-
latory protein (IRP)-1.
More importantly, the synthesis of iron receptors and 
absorption is regulated further by a liver-derived peptide, 
hepcidin, which functions as an iron regulatory hormone. 
When bodily iron demands are high, hepcidin levels are low 
and vice versa (12). When iron absorption is not required, 
hepcidin is released and binds to FPN-1 to inhibit the fur-
ther transportation of iron through enterocytes. Hepcidin is 
upregulated by a protein found on the surface of the liver 
and produced by the called human homeostatic iron reg-
ulator  (HFE) gene called HFE protein. They are expressed 
in response to high circulating iron levels and response to 
inflammation, infection, endotoxin, and p53 (2,3,9,12). HFE 
protein is a critical player in iron regulation and the likely 
culprit of dysfunction in most iron regulatory disorders. 
Hepcidin and iron sensing/signaling pathway
Body iron sensing is regulated by a signaling pathway. 
 Hepcidin is a peptide discovered by researchers investigat-
ing antimicrobial peptides in the early 2000s (15). Research-
ers were able to isolate hepcidin from human urine and was 
named from the basis of its actual synthesis (Hep-) and its 
antibacterial properties (-cidin) (15,16). It became evident 
that the peptide played a much larger and essential function 
in ensuring and maintaining the body’s proper serum iron 
levels. Although iron overload has been a recognized disor-
der since the 1900s, the disorder’s mechanism was unknown 
until hepcidin’s discovery (15). Today, hereditary hemochro-
matosis is now attributed to hepcidin deficiency.
Hepcidin’s primary mechanism is to act as a negative 
regulator of ferroportin, the principal iron regulatory 
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hormone (4,17). This protein is synthesized as an 84-amino 
acid precursor, broken down to its active form, consisting 
of 25-amino acids (16). In humans, this peptide is derived 
from the C-terminus end of the prepropeptide, encoded by 
a 0.4-Kilobase (kb) mRNA generated from three exons of 
a 2.5 kb gene on chromosome 19 (4). When hepcidin inhib-
its ferroportin, it prevents the cells from exporting iron back 
into the blood. Ferroportin is located on the basal mem-
brane of enterocytes and apical membrane of hepatocytes 
(4,17). Therefore, it will bind to ferroportin and decrease its 
functional activity through endocytosis from the cell surface 
and degrade it (4). Hepcidin also functions within the retic-
uloendothelial cells, the primary storage depot for iron, and 
inhibits the release of iron recycled from digested RBCs or 
mobilized from storage pools to cells that need it (4,17).
Hepcidin, ferritin, and TF are acute phase reactants. Iron 
plays a pivotal role in proliferating, feeding, and fueling the 
spread of harmful bacteria; ferritin and hepcidin increase 
to alleviate the amount of readily available serum iron, 
thus becoming positive acute phase reactants in response to 
inflammation (4). In contrast, TF is a negative acute phase 
reactant, lessening in response to inflammation to decrease 
active iron transportation throughout the blood (4).
Iron concentrations are influenced by multiple stimuli, 
such as iron body storage, erythropoiesis, hypoxia, and 
inflammatory states (16). During the elevated iron storage 
in the body, the levels of hepcidin increase to decrease the 
amount of iron absorbed (4). Whereas in situations like acute 
blood loss, hepcidin levels alleviate, and the bioavailable iron 
will increase. Similarly, in tissue hypoxia, the decreased oxy-
gen will trigger hepcidin production in the liver (4).
 Serum ferritin and TF receptor concentrations are altered 
in response. For example, following surgery, without preced-
ing infection, changes in these acute phase reactants’ concen-
trations can be observed and are like how the body responds 
to inflammation because of an infectious process. Iron sens-
ing can be triggered by two signals belonging to transform-
ing growth factor β (TF saturation and bone morphogenic 
proteins [BMP]) that regulate hepcidin expression. These 
signals are the extent of TF saturation and bone morpho-
genic proteins (BMP), a class of ligands of the transforming 
growth factor β superfamily.
Causes and genetics of iron overload
As discussed, the human body has several regulatory mech-
anisms to protect itself  against the damage caused by free 
iron. However, in some disorders, these regulatory mecha-
nisms are insufficient or fail, allowing free iron to overload 
our system (18). When overload occurs, some target organs 
such as the heart, liver, endocrine cells, gonads, and pancre-
atic islets are more vulnerable (18). The disorders that cause 
IO can be separated into mutations that cause an increase 
in iron absorption via hepcidin dysfunction and mutations 
that cause ineffective iron export from storage cells via 
deficiencies in ferroportin or ceruloplasmin (19,20). Com-
monly, it is a gene mutation and a combination of  environ-
mental factors, particularly alcohol intake of  more than 
60  g/day, coupled with an underlying gene mutation that 
ultimately contributes to the development of  clinically rel-
evant IO (21). 
The most common IO disorders are those that encompass 
hereditary hemochromatosis. There are four types of hemo-
chromatosis. Three are recessive mutations affecting the acti-
vation of hepcidin via HFE, HJV, HAMP, and TRF2. Type 4 
hemochromatosis/ ferroportin disease is an autosomal dom-
inant mutation in the hepcidin receptor FPN (22). The HFE 
protein is regulated through TfR-1 binding and endocytosis 
of diferric transferrin control synthesis (4). TfR-1 binds to 
HFE using a similar binding site as holotransferrin. When 
holotransferrin is elevated, it will displace the HFE from the 
TfR1 and allows HFE to signal the liver to increase hepcidin 
transcription (4).
Moreover, the HFE gene, protein, and hepcidin signaling 
are directed by the needed erythropoiesis requirement. Over-
all, the liver regulates hepcidin transcription reduction, allow-
ing iron to be absorbed according to the body’s demands (4). 
Therefore, mutation of one of the genes involved with hepci-
din or hepcidin results in extreme iron overload from uncon-
trolled iron absorption from the intestine.
The commonly occurring hemochromatosis is type 1 
HFE-related hemochromatosis. Typically caused by a muta-
tion of cysteine-to-tyrosine substitution at amino acid 282 
(C282Y), which carries a low clinical penetrance with variable 
expression (16). This mutation causes an inactivation in hep-
cidin, leading to dysregulation of iron absorption by entero-
cytes. If  clinically meaningful, symptoms appear between the 
ages of 40 and 60 years. A mutation in the SLCS401A1 gene 
causing ineffective iron export and a complete loss of ferro-
portin’s iron export function is responsible for Type 4 hemo-
chromatosis. This loss of function causes iron to accumulate 
in macrophages; thus, upregulating ferritin and iron release 
into plasma. Because the macrophages can handle the excess 
iron, it does not cause any clinically significant disease. The 
most lethal subtypes are Type 2A and 2B, caused by HJV 
and HAMP mutations, as they are known to be primarily 
responsible for lower hepcidin levels (23). 
Other IO syndromes include atransferrinemia, DMT-1 
deficiency, and aceruloplasminemia. Atransferrinemia is 
caused by a pathogenic mutation leading to low serum TF 
causing poor iron delivery to mature erythroblasts (6,16). 
DMT1 is a transmembrane protein in the brush-border 
membrane of duodenal enterocytes and plays a role in the 
use of iron by erythroid precursors (6,16,24). A mutation 
in the coding of the protein is infrequent. Acerulopasmin-
emia is an extremely rare mutation within the multicopper 
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ferroxidase family that is responsible for facilitating the efflux 
of iron and its release to TF with variable expression. This 
mutation is exceptionally toxic to neurons and is the only IO 
disorder with neurological manifestations (6,19,24).
The secondary causes of IO include ineffective erythropoi-
etic disorders such as thalassemia syndromes, sideroblastic 
anemia, myelodysplastic syndrome, parental iron overload, 
testosterone use, and end-stage liver disease (25). The causes 
of IO are usually because of the need for multiple iron trans-
fusions along with increased absorption of iron by the intes-
tine to provide more iron to produce erythrocytes (25).
Identifying symptoms and diagnosis
Regardless of the IO disorder etiology, severe iron overload 
leads to clinically significant IO disorder, characterized by 
deposition of hemosiderin in the liver and other organs. 
 Clinical manifestations are linked to the iron accumulation 
in the tissues and the organ’s ability to cope with oxidative 
management. Typically, organ damage is more commonly 
evident in males versus females, presumably because of men-
struation. Type 1 hemochromatosis carries the highest risk 
for cirrhosis and a two-fold risk for hepatocellular carci-
noma, and type 1A and type 2B are associated with death 
because of cardiac dysfunction (26,27). 
Hepatic injury is mediated by an inflammatory response 
by Kupffer cells that lead stellate and mesenchymal cells to 
produce excess collagen and cause fibrosis. Initially, iron 
deposition occurs in the cytoplasm of periportal hepatocytes. 
However, as iron load increases, the rest of the lobule along 
with the bile duct epithelium and Kupffer cells are affected. 
About 13 to 15 mg of iron/g of liver tissue is necessary for 
the development of cirrhosis. Normal individuals have less 
than 1000 ug/g dry weight of iron within liver tissue. Those 
with over 22,000 iron ug/g dry weight of iron almost cer-
tainly have cirrhosis (28). 
Diagnosis is usually incidental during routine labs as IO 
presents with nonspecific symptomatology that develops 
slowly. Although opinions vary, the guidelines from 2005–
2018 suggest that elevated ferritin of >300 ug/L in males 
and postmenopausal females and >200 ug/L in premeno-
pausal females with and increased fasting TF saturation 
>45% with or without symptoms indicate further investiga-
tion (11,12,26,27,29). Ferritin overestimates the amount of 
serum iron and can be influenced by alcohol use, inflamma-
tion, infection, metabolic syndrome, and other inflammatory 
states; thus, it is not a reliable diagnostic index for IO disor-
ders. Hemoglobin, mean corpuscular volume, TF saturation 
are other biochemical indices that further elucidate the eti-
ology of IO. Increased TF saturation level indicates unusual 
iron hemostasis because of increased intestinal iron absorp-
tion along with iron release from macrophages and other 
storage cells. 
Hyperferritinemia with normal to low TF saturation trig-
gers the identification of other pathologies such as cell necro-
sis, metabolic syndrome, alcohol use disorder, or mutations 
causing elevated ferritin levels. Microcytic anemia indicates 
that the IO disorder responsible is likely DMT1 deficiency, 
aceruloplasminemia, or atransferrinemia. Overall, liver 
biopsy is the gold standard in diagnosis and determine 
the amount of iron overload and degree of liver damage. 
However, quantitative magnetic resonance is a noninvasive 
modality to estimate the iron load in organs and is widely 
used (30). Genetic testing and screening are necessary to con-
firm the diagnosis and identify at-risk relatives (19). 
Individuals with a known family history of hereditary 
hemochromatosis (HH) should be screened for HFE gene 
mutations. Individuals who self-reported family history of 
HH had a sensitivity and specificity of 81% and 97%, respec-
tively, supporting family history as an accurate screening 
tool (31). 
In those patients who are not aware of their mutation 
status but have clinical manifestations, diagnosis can be 
confirmed by combining laboratory and diagnostic tests. 
Overall, guidelines do not recommend genetic testing 
amongst the general population. Testing for HFE mutation 
is not recommended because of its low penetrance, which 
only shows a small percentage of homozygous iron overload 
in individuals progressing to IO. Patients with unexplained 
arthritis, arthralgia, or Type 2 diabetes are not recommended 
to get tested for HH. However, testing should be considered 
in unexplained chronic liver disease with high serum levels of 
TF saturation (12,27,32,33). 
No further genetic testing is recommended if  tested indi-
viduals do not carry the C282Y or H63D alleles. Patients 
with H63D or S65C mutations but lacking the C282Y muta-
tion should be reassured that they are not at higher risk 
for IO. A biopsy is only recommended for confirmation if  
needed, to stage liver fibrosis or in the setting of serum ferri-
tin above 1000 mg/L, elevated AST, hepatomegaly, or above 
40 years of age. Otherwise, the American College of Gastro-
enterology (ACG) recommends contrast-enhanced magnetic 
resonance imaging (MRI) to measure liver iron concentra-
tion noninvasively (27).
Treatment
Guidelines agree that phlebotomy is the recommended first-
line treatment in HH (26,27,33). Treatment should begin in 
C282Y homozygotes with elevated serum ferritin of >300 
mg/mL in men and >200 mg/mL in women, combined with 
a serum TF saturation of >45%. Phlebotomy occurs weekly, 
removing an estimated ~500mL of blood to reduce serum 
ferritin level to a goal level of 50 to 100 ng/mL. The fre-
quency of phlebotomy occurs on a maintenance schedule of 
around 3–4 times a year after the goal level achievement (34).
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Erythrocytapheresis can be used as an alternative to phle-
botomy. This method targets and removes only RBCs, par-
ticularly in individuals suffering from hypoproteinemia or 
thrombocytopenia. It can remove up to 800mL of RBCs in 
volume during one session and requires less frequent removal 
every 2–3 weeks. However, the procedure is much more 
expensive than phlebotomy and is not recommended in rou-
tine cases (27). 
Chelation therapy is only suggested for patients who are 
intolerant or refractory to phlebotomies (27). While effec-
tive, chelating agents can have adverse effects. The three most 
common chelating agents: deferoxamine, deferiprone, and 
deferasirox, have the potential for renal and hepatic toxicity, 
which requires frequent laboratory monitoring, especially of 
creatinine, as there is an increased risk for acute renal failure 
(27). Additionally, these oral agents can also cause gastroin-
testinal upset, bleeding, pain, and rash, making compliance 
more difficult. A risk-benefit analysis should be considered 
when choosing chelation and the specific agent for each 
patient (35–39).
Proton pump inhibitors (PPIs) can reduce iron absorp-
tion by decreasing gastric acid secretion. Several studies have 
shown a reduction in the number of phlebotomies needed to 
achieve goal TF levels (40–42). However, contrary to EASL 
and ASLD guidelines, ACG 2019 recommends against PPI 
as a primary treatment of HH.
A diet low in iron, alcohol, meat, and vitamin C is recom-
mended with refraining from shellfish or undercooked pork 
because of an increased risk for infection (22). 
Liver transplant should be considered in all patients 
with HH and decompensated cirrhosis or hepatocellular 
 carcinoma.
Nonalcoholic fatty liver disease (NAFLD) related 
to iron overload
NAFLD is defined as the presence of hepatic steatosis with 
no secondary causes of hepatic fat accumulation (i.e., alco-
hol consumption, hepatitis). NAFLD afflicts patients world-
wide but is the most common amongst individuals living in 
the Western industrialized countries. Based on the severity of 
hepatic inflammation, NAFLD is subdivided into two cate-
gories: the milder NAFLD and the more severe nonalcoholic 
steatohepatitis (NASH). In NAFLD, there is an accumula-
tion of triglycerides within the hepatocytes in the absence of 
significant alcohol consumption (43). In contrast, in NASH, 
fatty build-up causes definitive lobar inflammation and cell 
death, leading to fibrosis and cirrhosis.
About 33% of patients with NAFLD exhibit evidence of 
disrupted iron homeostasis (44). These patients often have 
elevated serum ferritin levels with either normal or mild ele-
vation in TF saturation levels, and additionally, upon liver 
biopsy, they often have a hepatic iron disposition. The term 
“dysmetabolic iron overload syndrome (DIOS)” has is used 
to describe these findings (45).
Iron accumulation in NAFLD is secondary to the inhibi-
tion of iron use from hepatocytes (46). Impaired export leads 
to inflammation and metabolic derangements. That impacts 
iron regulators (hepcidin and ferroportin), TF receptors, fer-
ritin, and copper. 
An increase in the ferritin levels is a crucial key feature of 
iron dysregulation in patients with NAFLD. There appears 
to be a correlation between hyperferritinemia levels and 
the degree of histologic liver injury (46). In a large NASH 
study, serum ferritin concentration of more than 1.5 times, 
the upper limit of normal was associated with advanced liver 
fibrosis and NAFLD activity score (47).
Iron deposition in NALFD is found within the Kupffer 
cells and hepatocytes. The Kupffer cells are involved in ini-
tiating the inflammatory cascade when it responds to the 
uptake of oxidized lipoproteins and iron accumulation (48). 
In NAFLD, hepcidin expression was directly correlated with 
iron liver, indicating that these patients have an intact phys-
iologic response to hepcidin biosynthesis, unlike hemochro-
matosis (48).
Clinically, the excess iron caused by NAFLD causes simi-
lar iron overload to hemochromatosis. Excess unbound iron 
can catalyze the formation of toxic hydroxyl radicals and can 
result in lasting cellular damage. Therefore, DIOS can lead to 
long-term effects of hepatic damage, cardiovascular disease, 
and predisposing metabolic disorders, such as diabetes. Iron 
overload may also contribute to liver injury in NAFLD by 
adding stress to the endoplasmic reticulum within hepato-
cytes (46). In NAFLD, the excess iron generates an unfolded 
protein response and stress upon the endoplasmic reticulum 
within the hepatocytes. Similarly, iron overload upregulates 
cholesterol pathways, further potentiating NAFLD. Hence 
efforts to reverse or lessen the iron burden may improve or 
slow the progression of NAFLD (46).
Treatment for iron overload in NAFLD mainly focuses on 
reducing hepatic steatosis. That improves liver dysfunction 
and prevent further fibrosis. Recommendations for NAFLD 
treatment start with lifestyle changes, including weight loss, 
refraining from alcohol consumption, and exercise. A weight 
reduction of at least 5% of an individual’s body weight can 
improve fatty deposition. In a meta-analysis study, ≥ 5% 
body weight loss improved fatty liver disease, and loss of ≥ 
7% of body weight improved NALFD activity score (NAS) 
(49). For patients with diabetes and the presence of NASH, 
treatment should also target lowering glycated hemoglobin. 
Hyperferritinemia
Serum ferritin is a well-known positive acute-phase reactant, 
and its elevation is seen in any stress state. In these states, 
translation and transcription of ferritin are upregulated, and 
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